Filtered By:
Specialty: Hematology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 677 results found since Jan 2013.
Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis
CONCLUSIONS: Patients with morbid obesity on DOACs had similar risks of stroke/systemic embolism, lower rates of recurrent VTE and major bleeding events compared to those on VKAs. However, the certainty of evidence was low given that studies were mostly observational with high risk of confounding.PMID:34399433 | DOI:10.1055/a-1588-9155
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Tzu-Fei Wang Marc Carrier Karine Fournier Deborah M Siegal Gr égoire Le Gal Aur élien Delluc Source Type: research
Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation
In conclusion, in this cohort of post-discharge octogenarian patients with AF, the risk for all-cause death was similar in NOAC versus VKA users, after adjustment for baseline covariates. No differences in stroke and major bleeding events among these treatment groups were revealed.Graphic abstract
Source: Journal of Thrombosis and Thrombolysis - September 25, 2021 Category: Hematology Source Type: research
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research
Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study
CONCLUSION: In patients with AFF, liver cirrhosis was associated with an elevated risk of ischemic stroke, venous thromboembolism, and all evaluated bleeding complications.PMID:35229067 | PMC:PMC8867136 | DOI:10.1002/rth2.12668
Source: Thrombosis and Haemostasis - March 1, 2022 Category: Hematology Authors: Emil B Riahi Kasper Adelborg Lars Pedersen S øren R Kristensen Anette T Hansen Henrik T S ørensen Source Type: research
Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research
Visit-to-Visit Heart Rate Variability in the Prediction of Clinical Outcomes of Patients with Atrial Fibrillation
CONCLUSION: VVV-HR is an independent predictor for adverse clinical outcomes in patients with AF. A J-curve appearance was demonstrated for the effect of VVV-HR on all-cause death.PMID:37116533 | DOI:10.1055/s-0043-1768580
Source: Thrombosis and Haemostasis - April 28, 2023 Category: Hematology Authors: Rungroj Krittayaphong Warangkna Boonyapisit Poom Sairat Gregory Y H Lip Source Type: research
Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial
CONCLUSIONS: In this posthoc WR analysis of the mAFA-II trial, a mHealth-technology-implemented integrated care approach was effective in reducing the risk of the primary composite outcome of all-cause death, ischemic stroke or thromboembolism, and rehospitalization, even when prioritizing fatal events.PMID:37247623 | DOI:10.1055/s-0043-1769612
Source: Thrombosis and Haemostasis - May 29, 2023 Category: Hematology Authors: Giulio Francesco Romiti Yutao Guo Bernadette Corica Marco Proietti Hui Zhang Gregory Y H Lip mAF-App II trial investigators Source Type: research
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
CONCLUSION: Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.PMID:37369234 | DOI:10.1055/s-0043-1769735
Source: Thrombosis and Haemostasis - June 27, 2023 Category: Hematology Authors: Maxim Grymonprez Mirko Petrovic Tine L De Backer Stephane Steurbaut Lies Lahousse Source Type: research
